Treatment of myocardial dysfunction in sepsis: The toll-like receptor antagonist approach

Shock

Volumn 36, Issue 6, 2011, Pages 633-634

  Kimmoun, Antoine ^a,b   Levy, Bruno ^a,b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; ENDOTHELIN 1; ERITORAN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYSOZYME; LYSOZYME C; NITRIC OXIDE; PLACEBO; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOTOXEMIA; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; HYPOTENSION; MORTALITY; MYOCARDIAL DISEASE; NONHUMAN; NOTE; SEPSIS; SEPTIC SHOCK;

ANIMALS; DISACCHARIDES; ENDOTOXEMIA; FEMALE; MALE; SEPSIS; SUGAR PHOSPHATES; TOLL-LIKE RECEPTOR 4;

EID: 81755178368     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318237a37b     Document Type: Note

References (16)

1. Brun-Buisson C, Meshaka P, Pinton P, Vallet B: EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 30:580-588, 2004. (Pubitemid 38530092)
2. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100:483-490, 1984. (Pubitemid 14126735)
3. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, et al.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 282:2085-2088, 1998. (Pubitemid 29001265)
4. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA: Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104:271-280, 1999.
5. Baumgarten G, Knuefermann P, Nozaki N, Sivasubramanian N, Mann DL, Vallejo JG: In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of Toll-like receptor-4. J Infect Dis 183:1617-1624, 2001. (Pubitemid 32466699)
6. Tavener SA, Long EM, Robbins SM, McRae KM, Van Remmen H, Kubes P: Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circ Res 95:700-707, 2004. (Pubitemid 39331930)
7. Fallach R, Shainberg A, Avlas O, Fainblut M, Chepurko Y, Porat E, Hochhauser E: Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. J Mol Cell Cardiol 48:1236-1244, 2010.
8. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001. (Pubitemid 32204987)
9. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, et al.: Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4Ydirected endotoxin antagonist. J Pharmacol Exp Ther 304:1093-1102, 2003. (Pubitemid 36254422)
10. Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM: Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist in patients with severe sepsis. Crit Care Med 38:72-83, 2009.
11. Lynn M, Rossignol DP, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, Vargas R, D'Angelo T, Gotzkowsky S, McMahon FG: Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 187:631-639, 2003. (Pubitemid 36250027)
12. Czeslick E, Struppert A, Simm A, Sablotzki A: E5564 (eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes. Inflamm Res 55:511-515, 2006. (Pubitemid 44826742)
13. Baumgarten G, Knuefermann P, Schuhmacher G, Vervolgyi V, von Rappard J, Dreiner U, Fink K, Djoufack C, Hoeft A, Grohe C, et al.: Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia. Shock 25:43-49, 2006.
14. Ehrentraut S, Frede S, Stapel H, Mengden T, Grohe C, Fandrey J, Meyer R, Baumgarten G: Antagonism of lipopolysaccharide-induced blood pressure attenuation and vascular contractility. Arterioscler Thromb Vasc Biol 27:2170-2176, 2007. (Pubitemid 350287246)
15. Ehrentraut S, Lohner R, Schwedersk M, Ehrentraut H, Boehm O, Noga S, Langhoff P, Baumgarten G, Meyer R, Knuefermann P: In vivo Toll-like receptor 4 antagonism restores cardiac function during endotoxemia. Shock. 36:613-620, 2011. 635
16. Yeh C-H, Chou W, Chu C-C, So EC, Chang H-C, Wang J-J, Hsing C-H: Anticancer agent 2-methoxyestradiol improves survival in septic mice by reducing the production of cytokines and nitric oxide. Shock 36:510-516, 2011.